Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

August 04, 2015 2:58 PM ET


Company Overview of Kymab Limited

Company Overview

Kymab Limited, a biopharmaceutical company, engages in the discovery and development of human monoclonal antibody therapeutics. The company is using mouse embryonic stem cell technology to develop its Kymouse platform that focuses on encompassing the diversity of the B lymphocyte component of the human immune system, and has the potential for expansion of diversity beyond the normal human immune response. The company focuses on using the Kymouse platform for the discovery, development, and commercialization of antibody based medicines. Kymab Limited was founded in 2009 and is based in Cambridge, United Kingdom.

Meditrina (B260)

Babraham Research Campus

Cambridge,  CB22 3AT

United Kingdom

Founded in 2009


44 1223 833301


44 1223 839133

Key Executives for Kymab Limited

Chairman and Chief Executive Officer
Founder, Chief Scientific Officer, Consultant and Director
Chief Business Officer
Senior Vice President of Technology Development
Consultant Finance Director
Compensation as of Fiscal Year 2015.

Kymab Limited Key Developments

Kymab Limited Presents at BioCentury 22nd Annual Future Leaders in the Biotech Industry Conference, Mar-20-2015 10:30 AM

Kymab Limited Presents at BioCentury 22nd Annual Future Leaders in the Biotech Industry Conference, Mar-20-2015 10:30 AM. Venue: Millennium Broadway Hotel & Conference Center, New York, New York, United States.

Kymab Limited Presents at BIO-Europe Spring 2015, Mar-09-2015

Kymab Limited Presents at BIO-Europe Spring 2015, Mar-09-2015 . Venue: Paris Expo - Porte de Versailles, Hall 5, Paris, France.

Kymab Defends Patent Action in UK

Kymab announced that it has notified the English Court that it will defend the UK patent proceedings brought by Regeneron in respect of European patent EP1360287. Regeneron initiated these proceedings in September 2013. Kymab will defend the UK patent action on the grounds of non-infringement and invalidity of the patent. Earlier, in June 2013, Kymab opposed the equivalent Regeneron European patent in the European Patent Office. The opposition proceedings are pending.

Similar Private Companies By Industry

Company Name Region
ERA Consulting (UK) Limited Europe
Innovata Biomed Ltd. Europe
Lab M Limited Europe
Tocris Cookson Ltd. Europe
Bio Products Laboratory Ltd Europe

Recent Private Companies Transactions

No transactions available in the past 12 months.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Bertelsmann AG Europe
Rush University United States
Greater Houston Partnership United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact Kymab Limited, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at